

Safety Documentation

Please select the forms you require by selecting the check boxes below. You can select more than one.

✓ Risk Assessment
✓ Method Statement
✓ Chemicals COSHH

Once you have made your selections, scroll down and complete the forms.

<u>Buttons</u>: [+] will add a row to a list [X] will delete a row from a list

You may save this file to a local drive at any time.

When you have finished, save the file to a local drive and email it to your supervisor for authorisation.

<u>Supervisors</u> - There is a sign-off section at the end of the document set that must be completed.

Staff may "self authorise", (as a supervisor), but the forms must still be submitted to the DSO for approval.

IMPORTANT:

YOU <u>MUST NOT</u> START ANY PRACTICAL WORK UNTIL THESE FORMS HAVE BEEN RETURNED TO YOU WITH **BOTH** YOUR SUPERVISOR'S AND DSO'S APPROVAL SIGNATURES ATTACHED.

Please complete these fields					
School or Service	Wolfson School of Mechanical, Electrical and Manufacturing Engineering				
Department	CBE				
Originator name	Oliver Frost				
email address	o.g.frost@lboro.ac.uk				
Location	CBE, H25				
Project / Activity / 1	(Proof of concept for separation of young from old (senescent) cells – improving efficacy and safety for clinical use'				
Supervisor Name	Rob J Thomas				

Version: 2.19

© 2018 Loughborough University. All rights reserved



Risk Assessment

Risk Assessm	nent		Reference	SAF/MEME/7904 CBEBRA2
Location	CBE, H25	Originator	Oliver Fros	st
Project / Activity / Task	'Proof of concept for separation of young from old (se – improving efficacy and safety for clinical use'	nescent) cells		
Is this process risk a	ssessment for a:	○ General use	e	

Category 1: Machinery & v	vork equipment:				
Design and Construction	Mechanical hazards	Electrical hazards	Radiation hazards	+	
N/A	N/A	N/A	N/A	x	
Category 2: Workplace				+	
Slips/Trips/Falls on the level					
Category 3: Hazardous and/or Harmful substances					
Cancer causing substances					
Category 4: Work activity					
Lone working out of hours					
Category 5: Work organisa	ition			+	
N/A				X	

Explain the risks asso	ociated with these hazards				
People / Groups at risk Operator and people in proximity					X
Enter risk details here:-		Impact	Probability	Risk S	core
Slips/Trips/Falls on the le	evel	Harmful	Highly Unlikely		Low
What are the control measures	?	Lowers Impact	Lowers Probability	+	
Organise room to have r Reduce movement betw	nothing on the floor that can be a trip hazard. ween labs if possible.	Significantly	Significantly	x	
				Resid	dual Risk
					Low
People / Groups at risk	Operator and people in proximity				X
Enter risk details here:-		Impact	Probability	Risk S	core
Aerosols/splashes from	irritant substances & sensitiser	Harmful	Highly Unlikely	Low	
What are the control measures	?	Lowers Impact	Lowers Probability	+	
Work in fume hood or B	SC	Significantly	Significantly	x	
Wear PPE		Significantly	Significantly	x	

Process Risk Assessment Form (Continued)

			Resid	dual Risk
				Low
People / Groups at risk Operator only				X
Enter risk details here:-	Impact	Probability	Risk S	core
Lone Working out of hours	Slightly Harmful	Unlikely		Low
What are the control measures?	Lowers Impact	Lowers Probability	+	
Loughborough University Lone working policy to be followed, with the use of the lone working app and contacting security on occasions of lone working. Will send OOH 1st contact a text message on entry to the lab and another when leaving. Depending on the length of OOH work needed, further text updates will be used (hourly/2 hourly). permission to work out of hours must be obtained prior to work commencing. It is advised to inform security so that they are aware of your location on campus for the duration of your lone working/out of hours, and also inform Security when you leave the premises. Inform academic supervisor and a colleague of intention to lone work and state duration of stay. Ensure you have mobile phone on person at all times - security mobile number is 0800 526966 - security staff are also trained First Aiders Always remember to log out of lone working app when leaving building at completion of the work. Inform lab management of intention to work out of hours.	Significantly	Significantly	x	
Will be aware of all safety procedures (including for emergency), and numbers	Significantly	Significantly	x	
	•	_	Resi	dual Risk
		l l		Low

+ Add another Risk

Who may be at risk as a result of this activity?

Personnel Group	Maximum (Task setup/ Reconfiguration)	High (Performing the task)	Medium (Observing the task)	Low (Present, but not involved)	Lone Working (Out of hours)	No Exposure Permitted	Total
Academic Staff	0	0	0	0	0	0	0
Technical Staff	0	0	0	1	0	0	1
Research Staff (PDRA)	0	0	0	3	0	0	3
Research Students (PhD)	0	1	0	0	1	0	2
Students (Undergraduate / MSc)	0	0	0	0	0	0	0
Visitors	0	0	0	0	0	0	0
Others - Over-type as needed	0	0	0	0	0	0	0

Process Risk Assessment Form (Continued)

Personnel Group	Maximum (Task setup/ Re- configuration)	High (Performing the task)	Medium (Observing the task)	Low (Present, but not involved)	Lone Working (Out of hours)	No Exposure Permitted	Total
Total	0	1	0	4	1	0	6

With these controls in place, the risk is:

The activity is LOW RISK - and is effectively controlled



Safety Method Statement

Detailed sequential description of the process

Process step

·			Reference	SAF/MEME/7904	
Location	CBE, H25	Originator	Oliver Fro	st	
Project / Activity / Task	'Proof of concept for separation of young from old (send – improving efficacy and safety for clinical use'	escent) cells			
What equipment w	ill be used in this activity?			+	+
Centrifuge Tubes				X	X
BSC				X	X
Incubator				X	X
What training must	be completed to do this activity?			+	+
CBE Training (Complete				X	X
CBE Training Refresher	(Completed in November 2023)			X	X
What chemicals are InSolution Doxorubicin	being used? (These must be included in the CC	SHH Form)			+ x
5-Aza-2-deoxycytidine				X	X
Bafilomycin				Х	X
DDAO galactosidase (9	H-(1,3Dichloro-9,9-Dimethylacridin-2-One-7-yl) B-D-Galac	topyranoside		Х	X
Spill and accident p	rocedures.			4	+
1	identified in change rooms . Soak up with inert absorben closed container for disposal. As detailed in SOP039 on pa sity online system.		•		X
Procedure in the ev	ent of an emergency. (How to leave the process in a	safe condition	in such an e	event)	+
	ils of the user and name of the chemical asking not to mor continuously, make equipment safe then evacuate the bu s safe to do so				x
References.				4	+

Precautionary measures and comments

Safety Method Statement (Continued)

Process step	Precautionary measures and comments		
Cells will be grown in T175 flasks for a period of 3 days in the incubator in H25. Once they reach confluency the media will be aspirated and replaced with media containing 200 nM of "InSolution Doxorubicin, Hydrochloride" or 200 nM "5-Aza-2-deoxycytidine". These will be prepared by adding 0.4 μ L of the 10 mM "InSolution Doxorubicin, Hydrochloride" or 10 mM "5-Aza-2-deoxycytidine" stock solutions in 25 mL of DMEM cell culture media. Once the media is replaced the flasks will be placed back in the incubator for 48 hours. After 48 hours the media will be aspirated and replaced with normal DMEM media and cells will be cultured for another 10 days. After 10 days, the media will be aspirated and treated with 0.1 μ M of Bafilomycin for 1 hour in the incubator. This will be prepared by diluting 6 μ L of 400 μ M Bafilomycin stock solution in 25 mL of DMEM culture media. After 1 hour the media will be aspirated and cells will be treated for 2 hours with 20 μ M DDAO galactosidase in the incubator. This will be prepared by diluting 1 μ L of 20 mM DDAO galactosidase stock solution in 10 mL PBS. After this, cells will be washed with PBS twice, detached using Trypsin and analyzed with a Flow cytometer. FACSCanto	All work will be done in BSCs in sterile conditions due to the work on cell cultures. Personal PPE equipment will be worn at all times and waste disposal will be done as described in this COSSH form.	x	

Loughborough University

COSHH Form


Reference SAF/MEME/2181-2184

Location	CBE, H25	Originator	Oliver Frost
	'Proof of concept for separation of young from old (sep	escent) cells	

Project / Activity / Task 'Proof of concept for separation of young from old (senescent) cel – improving efficacy and safety for clinical use'

ımpro-	ving emedey and safety for		
CHEMICAL NAME InSolution Doxorubicin, Hydrochloride		High OVERAL	X .L
CAS No. 25316-40-9 W.E.L. (Itel / stel)	Amount Period of use (hrs) 0.004 ml 48	The process is: Physical State	n
This chemical has a high health risk asso	ociated with it.		
Hazard Statement a		Precaution Statement and Description	+
H302 Harmful if swallowed.		P201 Obtain special instructions before use.	x
H340 May cause genetic defects.		P202 Do not handle until all safety precautions have been read and understood.	x
H350 May cause cancer.		P264 Wash thoroughly after handling.	x
H360FD May damage fertility. May dar	mage the unborn child.	P270 Do no eat, drink or smoke when using this product.	x
		P301 + P312 IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unw	x
		P308 + P313 IF exposed or concerned: Get medical advice/attention.	x
Justify the use of this chemical:		This chemical is essential for inducing stem cell senescence. It is widely used in other groups and research facilities and it is the gold standard for inducing cell aging. Currently there are no other safer alternatives in existence Chemical will be used to induce stem cell senescence. Once cells have been treated with 4 ul of Doxorubicin diluted in 20 ml of DMEM cell culture media (to achieve 20 nM of Doxorubicin) for 48 hours in the incubator, the solution will be aspirated and replaced with fresh DMEM cell culture media without Doxorubicin	
How will the precautions listed	d above be implemented?		
side fastening white laboratory good practice, without touchin gloves will be disposed of as bi procedure will be undertaken v contact with skin.	y coat with elasticated sleed ig the outer surface, thereb ohazardous waste (SOP00) within a BSC, thereby ensur be disposed in the cytotox	e safe handing and avoid contact with skin. These include a standard ves, gloves, safety glasses. Gloves will be removed in accordance with by avoiding skin contact with the substance. Once removed, used 3) and will be placed into the autoclave waste stream. The entire ring adequate ventilation and reducing the risk spillage or getting in kic boxes (purple) while liquid waste will be placed in a single container	
Special Storage and Containm	ent Measures	Disposal Method	+
-20C appropriately labelled		Aqueous waste - Check with Technician or Supervisor	x
How will spillages be dealt wi	th?	Please note: any material used to clean up a spill of hazardous material must also be disposed of as hazardous material. Click here to see spill procedures	
1 -	sharps container while all	disposed of through the cytotoxic waste route. All solids will be liquid will be placed in carefully labeled glass bottles before placing in ling to SOP038.	

COSHH Form (Continued)



COSHH Form (Continued)

H319 Causes serious eye irritation.		P261 Avoid breathing dust/fume/gas/mist/vapours/spray.	x	
H335 May cause respiratory irritation.		P280 Wear protective gloves/protective clothing/eye protection/face protection.	x	
H315 Causes skin irritation.		P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remov	x	
		P302 + P352 IF ON SKIN: Wash with plenty of soap and water.	x	
How will the precautions liste	d above be implemented?			
side fastening white laborator good practice, without touching gloves will be disposed of as b procedure will be undertaken contact with skin.	y coat with elasticated sleed ng the outer surface, therekt iohazardous waste (SOP00) within a BSC, thereby ensubed be disposed in the cytotox	e safe handing and avoid contact with skin. These include a standard ves, gloves, safety glasses. Gloves will be removed in accordance with by avoiding skin contact with the substance. Once removed, used 3) and will be placed into the autoclave waste stream. The entire ring adequate ventilation and reducing the risk spillage or getting in kic boxes (purple) while liquid waste will be placed in a single container		
Special Storage and Containr	ment Measures	Disposal Method	+	
-20C appropriately labelled		Aqueous waste - Check with Technician or Supervisor	x	
How will spillages be dealt with?		Please note: any material used to clean up a spill of hazardous material must also be disposed of as hazardous material. Click here to see spill procedures		
	c sharps container while all	disposed of through the cytotoxic waste route. All solids will be liquid will be placed in carefully labeled glass bottles before placing in ling to SOP038.		
CHEMICAL NAME	1	Hazard Rating	X	
DDAO galactosidase (9H- (1,3-Dichloro-9,9-		Low OVERAL	LL	
CAS No.	Amount Period of	The process is: Physical State Exposure Skin Potential		
W.E.L. (Itel / stel)	used use (hrs) 0.001 ml 1	Semi Closed Non-Volatile Liquid Inhaled Ingested Low		
Hazard Statement a	and Description	Precaution Statement and Description	+	
No Hazard Statements applicable		No Precaution statements applicable	x	
How will the precautions liste	d above be implemented?			
side fastening white laborator good practice, without touching gloves will be disposed of as b	y coat with elasticated slee ng the outer surface, therek iohazardous waste (SOP00)	e safe handing and avoid contact with skin. These include a standard ves, gloves, safety glasses. Gloves will be removed in accordance with by avoiding skin contact with the substance. Once removed, used 3) and will be placed into the autoclave waste stream. The entire ring adequate ventilation and reducing the risk spillage or getting in		
Special Storage and Containr	ment Measures	Disposal Method	+	
-20C appropriately labelled		Aqueous waste - Check with Technician or Supervisor	x	
How will spillages be dealt w	ith?	Please note: any material used to clean up a spill of hazardous material must also be disposed of as hazardous material.		
		Click here to see spill procedures		

+ Add another chemical

Statement of work (Process to be undertaken)

Cultured cells will be treated with "In solution Doxorubicin" or "5-Aza-2-deoxycytidine" for 48 hours before removing it and replacing the cell culture media with media without Doxorubicin. After 7 days in culture, the media will be removed and

Show image

COSHH Form (Continued)

cells will be treated with Bafilomycin A1 for 1 hour in the incubator followed by a 2 hour treatment with DDAO galactosidase. After two hours the cells be detached using Trypsin and analysed with a flow cytometer. Personal protection requirements not covered in the precaution statements above.

Closed shoes and overshoes (CBE).

Sources of information and references

https://www.sigmaaldrich.com/catalog/product/mm/504042? lang=en®ion=GB

https://www.sigmaaldrich.com/catalog/product/sigma/a3656?

lang=en®ion=GB

https://www.fishersci.co.uk/shop/products/bafilomycin-a1-95-

acrosorganics/

10295441

Reference to **existing approved** Risk Assessment

CBE/BRA/096

With the current controls, the risk of using these chemicals is: Medium

Supervisor to check that the process involving the safe use of these chemicals has been satisfactorily evaluated



Supervisor and Departmental Safety Office (DSO) Sign-off.

Supervisors

Please check the documents above and if you want to approve them:

- 1) Electronically sign this document
- 2) Save it to a local drive (You will be prompted to do this)
- 3) eMail the signed document to the DSO.

DSO

Please review the documents above and if you want to approve them:

 Enter the reference numbers Electronically sign this docun Save it to a local drive (You w eMail the signed document to 	nent vill be prompted to do this)		
IF YOU DO NOT WANT TO AUTHORISE THE FORMS, Please do not sign the form, but click the "Not Approved" check-box and return it to the originator by email stating why and what you expect them to do to put it right in the comments box below.			Not Approved
Supervisors Signature			
	Form Reference Numbers	 5	
Risk Assessment SAF/MEME/7904 CBEBR	Method Statement SAF/MEME/7904	COSHH Assessment SAF/MEME/2181-2184	
DSO Signature			
	this activity	-	18 Jan 2025
Review comments			

Oliver Frost 18-Jan-2024 Page 10 of 10